[{"id":"0908ebfc-d15b-456b-ac37-d0125231481b","acronym":"SUKSES-B2","url":"https://clinicaltrials.gov/study/NCT04939662","created_at":"2021-06-25T22:54:09.478Z","updated_at":"2025-02-25T14:59:57.998Z","phase":"Phase 2","brief_title":"Olaparib and Bevacizumab in Relapsed Small Cell Lung Cancer Subjects","source_id_and_acronym":"NCT04939662 - SUKSES-B2","lead_sponsor":"Se-Hoon Lee","biomarkers":" BRCA1 • BRCA2 • SLFN11 • BRCA • RAD51 • RAD51B • RAD51C • RAD50 • NBN • RAD54L • WRN • POU2F3 • RAD52 • RECQL5 • RECQL • RECQL4 • RPA1","pipe":" | ","alterations":" RAD51C mutation • RAD51D mutation • RAD51B mutation • BRCA mutation • RAD54L mutation","tags":["BRCA1 • BRCA2 • SLFN11 • BRCA • RAD51 • RAD51B • RAD51C • RAD50 • NBN • RAD54L • WRN • POU2F3 • RAD52 • RECQL5 • RECQL • RECQL4 • RPA1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RAD51C mutation • RAD51D mutation • RAD51B mutation • BRCA mutation • RAD54L mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Lynparza (olaparib)"],"overall_status":"Completed","enrollment":" Enrollment 25","initiation":"Initiation: 06/11/2021","start_date":" 06/11/2021","primary_txt":" Primary completion: 10/27/2023","primary_completion_date":" 10/27/2023","study_txt":" Completion: 10/27/2023","study_completion_date":" 10/27/2023","last_update_posted":"2024-01-01"},{"id":"b9646e03-3b93-41fe-a534-1decec5bf67f","acronym":"","url":"https://clinicaltrials.gov/study/NCT05042934","created_at":"2021-09-13T14:56:00.294Z","updated_at":"2024-07-02T16:36:17.321Z","phase":"Phase 1b/2","brief_title":"Lurbinectedin With or Without Irinotecan in Treating Patients With Relapsed or High Risk Metastatic Ewing Sarcoma","source_id_and_acronym":"NCT05042934","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" EWSR1 • FLI1 • WRN • RECQL","pipe":"","alterations":" ","tags":["EWSR1 • FLI1 • WRN • RECQL"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e irinotecan • Zepzelca (lurbinectedin)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 09/15/2021","start_date":" 09/15/2021","primary_txt":" Primary completion: 08/30/2022","primary_completion_date":" 08/30/2022","study_txt":" Completion: 08/30/2022","study_completion_date":" 08/30/2022","last_update_posted":"2022-02-10"},{"id":"81487a0e-81e3-441c-b593-12da8e76c7d4","acronym":"SUKSES-B","url":"https://clinicaltrials.gov/study/NCT03009682","created_at":"2021-01-18T06:59:12.038Z","updated_at":"2024-07-02T16:36:34.418Z","phase":"Phase 2","brief_title":"Olaparib Monotherapy in Relapsed Small Cell Lung Cancer Patients With HR Pathway Gene Mutations Not Limited to BRCA 1/2 Mutations, ATM Deficiency or MRE11A Mutations","source_id_and_acronym":"NCT03009682 - SUKSES-B","lead_sponsor":"Samsung Medical Center","biomarkers":" BRCA1 • BRCA2 • ATM • RAD51 • RAD51B • RAD51C • RAD50 • NBN • RAD54L • WRN • RAD52 • RECQL5 • RECQL • RECQL4 • RPA1","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation • RAD51C mutation • RAD51D mutation • RAD50 mutation • RAD51B mutation • BLM mutation • MRE11A mutation • RAD54L mutation • NBN mutation • WRN mutation • RAD52 mutation • RECQL mutation • RECQL4 mutation • RECQL5 mutation • RPA1 mutation","tags":["BRCA1 • BRCA2 • ATM • RAD51 • RAD51B • RAD51C • RAD50 • NBN • RAD54L • WRN • RAD52 • RECQL5 • RECQL • RECQL4 • RPA1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation • RAD51C mutation • RAD51D mutation • RAD50 mutation • RAD51B mutation • BLM mutation • MRE11A mutation • RAD54L mutation • NBN mutation • WRN mutation • RAD52 mutation • RECQL mutation • RECQL4 mutation • RECQL5 mutation • RPA1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib)"],"overall_status":"Completed","enrollment":" Enrollment 15","initiation":"Initiation: 08/01/2016","start_date":" 08/01/2016","primary_txt":" Primary completion: 01/01/2021","primary_completion_date":" 01/01/2021","study_txt":" Completion: 01/01/2021","study_completion_date":" 01/01/2021","last_update_posted":"2021-02-18"}]